Will Gut Microbiota Help Design the Next Generation of GLP-1-Based Therapies for Type 2 Diabetes?
Where this comes from
- Record sourced from PubMed, PMID 28683295.
- Also identified by DOI 10.1016/j.cmet.2017.06.009.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Glucagon-like peptide one (GLP-1)-based therapies for reducing hyperglycemia in type 2 diabetic patients are efficient, though some individuals develop GLP-1 resistance. In a recent issue of Cell Metabolism, Grasset et al. (2017) demonstrated that GLP-1 sensitivity is modulated by gut bacteria through NO signaling in the enteric nervous system.
Medical subject headings
- Diabetes Mellitus, Type 2
- Gastrointestinal Microbiome
- Glucagon-Like Peptide 1
- Hypoglycemic Agents
- Incretins